SARS-CoV-2.

Ran Zhang1,2, Lan Huang3, Xiaohan Zhang4

  • 1School of Basic Medicine Sciences, Anhui Medical University, Hefei, Anhui 230031, PR China.

PubMed
概括

研究人员开发了一种高通量蛋白质组学平台,用于选纳米体对抗SARS-CoV-2变种. 两个纳米体,C-282和C-39,对多种变体表现出广泛的中和活性,提供了潜在的未来治疗方法.